XDR Acinetobacter — SCE Infectious Diseases MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Start cefiderocol after specialist review
NICE recommends cefiderocol within its marketing authorisation for severe susceptible drug-resistant Gram-negative infection only when other suitable treatments are unavailable, with microbiology or infectious-disease specialist advice. Its SmPC includes HAP/VAP experience but warns of increased mortality observed in critically ill carbapenem-resistant infections, particularly Acinetobacter, so this is a restricted specialist decision rather than routine preference.
Reference: NICE AMR2: https://www.nice.org.uk/guidance/AMR2/chapter/1-recommendations; cefiderocol SmPC: https://www.medicines.org.uk/emc/product/11771/smpc